Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

122 results

Filters applied: . Clear all
Page 1
Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT).
Burmester GR, Van den Bosch F, Tesser J, Shmagel A, Liu Y, Khan N, Camp HS, Kivitz A. Burmester GR, et al. Among authors: van den bosch f. J Rheumatol. 2024 Apr 15:jrheum.2023-1062. doi: 10.3899/jrheum.2023-1062. Online ahead of print. J Rheumatol. 2024. PMID: 38621793
OBJECTIVE: To report 5-year efficacy and safety of upadacitinib in rheumatoid arthritis (RA) from the phase 3 long-term extension (LTE) of SELECT-NEXT. METHODS: Patients on stable conventional synthetic disease-modifying antirheumatic drugs were randomized to upadacitinib …
OBJECTIVE: To report 5-year efficacy and safety of upadacitinib in rheumatoid arthritis (RA) from the phase 3 long-term extension (LT …
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update.
Gossec L, Kerschbaumer A, Ferreira RJO, Aletaha D, Baraliakos X, Bertheussen H, Boehncke WH, Esbensen BA, McInnes IB, McGonagle D, Winthrop KL, Balanescu A, Balint PV, Burmester GR, Cañete JD, Claudepierre P, Eder L, Hetland ML, Iagnocco A, Kristensen LE, Lories R, Queiro R, Mauro D, Marzo-Ortega H, Mease PJ, Nash P, Wagenaar W, Savage L, Schett G, Shoop-Worrall SJW, Tanaka Y, Van den Bosch FE, van der Helm-van Mil A, Zabotti A, van der Heijde D, Smolen JS. Gossec L, et al. Among authors: van den bosch fe. Ann Rheum Dis. 2024 Mar 18:ard-2024-225531. doi: 10.1136/ard-2024-225531. Online ahead of print. Ann Rheum Dis. 2024. PMID: 38499325 Free article.
Non-steroidal anti-inflammatory drugs should be used in monotherapy only for mild PsA and in the short term; oral glucocorticoids are not recommended. In patients with peripheral arthritis, rapid initiation of conventional synthetic disease-modifying antirheumatic drugs is …
Non-steroidal anti-inflammatory drugs should be used in monotherapy only for mild PsA and in the short term; oral glucocorticoids are …
Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE.
Fleischmann R, Blanco R, Van den Bosch F, Bessette L, Song Y, Penn SK, McDearmon-Blondell E, Khan N, Chan K, Mysler E. Fleischmann R, et al. Among authors: van den bosch f. Rheumatol Ther. 2024 Mar 18. doi: 10.1007/s40744-024-00658-1. Online ahead of print. Rheumatol Ther. 2024. PMID: 38498140 Free article.
INTRODUCTION: This study aimed to describe the long-term efficacy and safety of upadacitinib and adalimumab through 228 weeks following immediate switch to the alternate therapy with a different mechanism of action (MoA) in patients with rheumatoid arthritis (RA) not achie …
INTRODUCTION: This study aimed to describe the long-term efficacy and safety of upadacitinib and adalimumab through 228 weeks followi …
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial.
Östör A, Van den Bosch F, Papp K, Asnal C, Blanco R, Aelion J, Carter K, Stakias V, Lippe R, Drogaris L, Soliman AM, Chen MM, Padilla B, Kivitz A. Östör A, et al. Among authors: van den bosch f. Rheumatol Ther. 2024 Mar 18. doi: 10.1007/s40744-024-00657-2. Online ahead of print. Rheumatol Ther. 2024. PMID: 38498139 Free article.
INTRODUCTION: Long-term therapeutic options providing durable response and tolerability are needed for psoriatic arthritis (PsA). ...
INTRODUCTION: Long-term therapeutic options providing durable response and tolerability are needed for psoriatic arthritis (PsA). ...
Goodbye to the term 'ankylosing spondylitis', hello 'axial spondyloarthritis': time to embrace the ASAS-defined nomenclature.
van der Heijde D, Molto A, Ramiro S, Braun J, Dougados M, van Gaalen FA, Gensler LS, Inman RD, Landewé RBM, Marzo-Ortega H, Navarro-Compán V, Phoka A, Poddubnyy D, Protopopov M, Reveille J, Rudwaleit M, Sampaio-Barros P, Sepriano A, Sieper J, Van den Bosch FE, van der Horst-Bruinsma I, Machado PM, Baraliakos X. van der Heijde D, et al. Among authors: van den bosch fe. Ann Rheum Dis. 2024 Apr 11;83(5):547-549. doi: 10.1136/ard-2023-225185. Ann Rheum Dis. 2024. PMID: 38071514
Ankylosing spondylitis (AS) is the historic term used for decades for the HLA-B27-associated inflammatory disease affecting mainly the sacroiliac joints (SIJ) and spine. ...These are important changes in the field, as experts in axSpA are now in agreement that the term …
Ankylosing spondylitis (AS) is the historic term used for decades for the HLA-B27-associated inflammatory disease affecting mainly th …
PET-based radiomics signature can predict durable responses to CAR T-cell therapy in patients with large B-cell lymphoma.
Ligero M, Simó M, Carpio C, Iacoboni G, Balaguer-Montero M, Navarro V, Sánchez-Salinas MA, Bobillo S, Marín-Niebla A, Iraola-Truchuelo J, Abrisqueta P, Sala-Llonch R, Bosch F, Perez-Lopez R, Barba P. Ligero M, et al. Among authors: bosch f. EJHaem. 2023 Sep 11;4(4):1081-1088. doi: 10.1002/jha2.757. eCollection 2023 Nov. EJHaem. 2023. PMID: 38024636 Free PMC article.
Chimeric antigen receptor (CAR) T-cell therapy is a promising treatment option for relapsed or refractory (R/R) large B-cell lymphoma (LBCL). However, only a subset of patients will present long-term benefit. In this study, we explored the potential of PET-based radiomics …
Chimeric antigen receptor (CAR) T-cell therapy is a promising treatment option for relapsed or refractory (R/R) large B-cell lymphoma (LBCL) …
Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 study.
Mease P, Setty A, Papp K, Van den Bosch F, Tsuji S, Keiserman M, Carter K, Li Y, McCaskill R, McDearmon-Blondell E, Wung P, Tillett W. Mease P, et al. Among authors: van den bosch f. Clin Exp Rheumatol. 2023 Nov;41(11):2286-2297. doi: 10.55563/clinexprheumatol/8l7bbk. Epub 2023 Jul 5. Clin Exp Rheumatol. 2023. PMID: 37404160 Free article. Clinical Trial.
OBJECTIVES: To assess the long-term safety and efficacy of upadacitinib in patients with psoriatic arthritis (PsA) and an inadequate response (IR) to biologic disease-modifying anti-rheumatic drugs (bDMARDs) who completed up to 152 weeks of treatment in the SELECT-PsA 2 st …
OBJECTIVES: To assess the long-term safety and efficacy of upadacitinib in patients with psoriatic arthritis (PsA) and an inadequate …
ASAS consensus definition of early axial spondyloarthritis.
Navarro-Compán V, Benavent D, Capelusnik D, van der Heijde D, Landewé RB, Poddubnyy D, van Tubergen A, Baraliakos X, Van den Bosch FE, van Gaalen FA, Gensler L, López-Medina C, Marzo-Ortega H, Molto A, Pérez-Alamino R, Rudwaleit M, van de Sande M, Sengupta R, Weber U, Ramiro S. Navarro-Compán V, et al. Among authors: van den bosch fe. Ann Rheum Dis. 2023 Jun 15:ard-2023-224232. doi: 10.1136/ard-2023-224232. Online ahead of print. Ann Rheum Dis. 2023. PMID: 37321799
OBJECTIVES: To develop a consensual definition for the term 'early axial spondyloarthritis-axSpA'-and 'early peripheral spondyloarthritis-pSpA'. ...
OBJECTIVES: To develop a consensual definition for the term 'early axial spondyloarthritis-axSpA'-and 'early peripheral spondyloarthr …
EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis.
Zabotti A, De Marco G, Gossec L, Baraliakos X, Aletaha D, Iagnocco A, Gisondi P, Balint PV, Bertheussen H, Boehncke WH, Damjanov NS, de Wit M, Errichetti E, Marzo-Ortega H, Protopopov M, Puig L, Queiro R, Ruscitti P, Savage L, Schett G, Siebert S, Stamm TA, Studenic P, Tinazzi I, Van den Bosch FE, van der Helm-van Mil A, Watad A, Smolen JS, McGonagle DG. Zabotti A, et al. Among authors: van den bosch fe. Ann Rheum Dis. 2023 Sep;82(9):1162-1170. doi: 10.1136/ard-2023-224148. Epub 2023 Jun 9. Ann Rheum Dis. 2023. PMID: 37295926 Free article.
The 10 PtC highlight arthralgia and imaging abnormalities as key elements of subclinical PsA that can be used as potential short-term predictors of PsA development and useful items to design clinical trials for PsA interception. Traditional risk factors for PsA development …
The 10 PtC highlight arthralgia and imaging abnormalities as key elements of subclinical PsA that can be used as potential short-term …
The value of volunteer surveillance for the early detection of biological invaders.
van den Bosch F, McRoberts N, Bourhis Y, Parnell S, Hassall KL. van den Bosch F, et al. J Theor Biol. 2023 Mar 7;560:111385. doi: 10.1016/j.jtbi.2022.111385. Epub 2022 Dec 21. J Theor Biol. 2023. PMID: 36565952
Since we are interested in early detection we calculate the Z% upper limit of the one sided confidence interval of the incidence (fraction infected) and use the term maximum expected plausible incidence for this. We compare the maximum plausible incidence when the expert s …
Since we are interested in early detection we calculate the Z% upper limit of the one sided confidence interval of the incidence (fraction i …
122 results